In cultured intact LLC-PK1 renal epithelial cells, a nonhydrolyzable ATP analogue, ATP gamma S, inhibits AVP-stimulated cAMP formation. In LLC-PK1 membranes, several ATP analogues inhibit basal, GTP-, forskolin-, and AVP-stimulated adenylate cyclase activity in a dose-dependent manner. The rank order potency of inhibition by ATP analogues suggests that a P2y type of ATP receptor is involved in this inhibition. The compound ATP gamma S inhibits agonist-stimulated adenylate cyclase activity in solubilized and in isobutylmethylxanthine (IBMX) and quinacrine pretreated membranes, suggesting that ATP gamma S inhibition occurs independent of AVP and A1 adenosine receptors and of phospholipase A2 activity. The ATP gamma S inhibition of AVP-stimulated adenylate cyclase activity is not affected by pertussis toxin but is attenuated by GDP beta S, suggesting a possible role for a pertussis toxin insensitive G protein in the inhibition. Exposure of intact LLC-PK cells to ATP gamma S results in a significant increase in protein kinase C activity. However, neither of two protein kinase C inhibitors (staurosporine and H-7) prevents ATP gamma S inhibition of AVP-stimulated adenylate cyclase activity, suggesting that this inhibition occurs by a protein kinase C independent mechanism. These findings suggest the presence of functional P2y purinoceptors coupled to two signal transduction pathways in cultured renal epithelial cells. The effect of P2y purinoceptors to inhibit AVP-stimulated adenylate cyclase activity may be […]
Introduction
Extracellular purines such as adenosine and adenine nucleotides such as ATP interact with cell surface receptors to regulate several physiologic processes (1, 2) . Two general classes of purinergic receptors exist (1) (2) (3) . One class is activated by adenosine and blocked by methylxanthines. These receptors are coupled to adenylate cyclase via G proteins in an inhibitory (A, receptor) and a stimulatory (A2 receptor) fashion. A second class of purinergic receptors is activated by ATP and is insensitive to methylxanthines. This class ofreceptor, referred to as P2 purinergic receptors, can be further subdivided into P2, and P2, subtypes based on relative potencies of synthetic ATP analogues (3) . There is limited information on the biochemical events involved in P2 receptor action. In some cell types, P2 receptors appear to be coupled via G proteins to activation of phosphoinositideand phosphatidylcholine-specific phospholipase C activity (4) (5) (6) (7) (8) .
Several studies have delineated an important role for Al and possibly A2 adenosine receptors in regulation of renal blood flow, glomerular filtration rate, renin secretion, and renal tubular transport processes (9) (10) (11) (12) (13) (14) (15) . There is, however, very limited information on the presence and functional significance of ATP responsive P2 purinergic receptors on renal epithelial cells (16) (17) (18) (19) (20) (21) . These studies were undertaken to examine the effect of several ATP analogues on biochemical responses in cultured renal epithelial LLC-PK1 cells. Our results suggest the presence of P2y purinergic receptors coupled to both inhibition of adenylate cyclase and stimulation of protein kinase C activity in these cells.
Methods
Materials. Arginine vasopressin, guanosine triphosphate (GTP), guanosine 5'-O-(2-thiodiphosphate, [GDPf3S]'), staurosporine, quinacrine dihydrochloride and 4#-phorbol 12-myristate 13-acetate (PMA) were obtained from Sigma Chemical Co., St. Louis, MO. Adenosine 5'-0-3thiotriphosphate, (ATPyS), fl, y-methyleneadenosine 5'-triphosphate, (f3, yATP), and 2-methylthioadenosine 5'-triphosphosate, (2 MeATP) were purchased from Research Biochemicals, Natick, MA. Phosphatidylserine, diolein, and l-oleoyl-2-acetyl-glycerol (OAG) were purchased from Avanti Polar Lipids, Inc., Birmingham, AL. Forskolin, 3-isobutyl-I -methylxanthine (IBMX) and H-7 (1-1 5-isoquinolonylsulfonyl)-2-methylpiperazine) were Cell culture and enzyme assays. LLC-PK1 cells, crude membranes, and particulate and soluble cell fractions were prepared as previously described (22) (23) (24) . Adenylate cyclase, cAMP phosphodiesterase, cAMP, protein kinase C, and total protein assays were performed exactly as described in recent publications from our laboratory (22) (23) (24) (25) (26) .
Statistical analyses. For adenylate cyclase analyses, all assays were performed in triplicate and the mean of the three determinations considered an n of 1. For cAMP analyses, each tissue culture well was considered an n of 1. All calculations and analyses were carried out using an ATT PC-6300 desktop computer (Iverson, NJ) and ABSTAT software (Parker, CO). All data are expressed as the mean±SE. Statistical analyses were performed using paired or unpaired Student's t test and analysis of variance where appropriate. A P value < 0.05 is considered significant.
1. Abbreviations used in this paper: GDPBS, guanosine thiodiphosphate staurosporine; IBMX, isobutyl methylxanthine; MeATP, methylthioadenosine triphosphate; OAG, oleoyl-acetyl-glycerol.
Results
Effect ofA TPyS on A VP-stimulated cAMPformation in intact LLC-PK, cells. In initial studies, we measured the effect of ATP-yS, a nonhydrolyzable ATP analogue with known P2Y receptor site activity, on hormone-stimulated cAMP formation in intact LLC-PKI cells. Cells were pretreated for 30 min with RO-20 1724 (IO-' M), a phosphodiesterase inhibitor that is not an adenosine receptor antagonist. As shown in Table I , ATPyS (10-4 M) significantly inhibits AVP-stimulated cAMP formation in intact LLC-PK, cells.
Effect ofA TP analogues on basal and agonist-stimulated adenylate cyclase activity in LLC-PK, crude cell membranes. Our cAMP results suggest that ATPyS inhibits cAMP formation. To determine if ATPyS inhibits agonist-stimulated adenylate cyclase activity, the studies demonstrated in Fig. 1 were carried out in LLC-PK1 crude membranes. At concentrations greater than IO-' M, ATPyS significantly inhibits arginine vasopressin-stimulated adenylate cyclase activity. Between 10-4 and 10-8 M ATPyS, 25-40% inhibition occurs while 90% inhibition occurs at 10-3 M.
To better delineate the mechanism ofATP-induced inhibition of adenylate cyclase activity, we measured the effects of three ATP analogues (/3, yATP, 2 MeATP, and ATPyS) on adenylate cyclase activity in crude LLC-PK, membranes in paired studies. These analogues were selected since previous studies suggest that the P2Y receptor subtype expresses a potency order of 2 MeATP > ATP > fl, yATP, whereas the P2, receptor subtype expresses a rank order of potency of fl, yATP Role ofA VP and A, adenosine receptors and ofphospholipase A2 in ATPyS inhibition of adenylate cyclase activity in LLC-PK, cell membranes. To better delineate the mechanism ofATP inhibition ofadenylate cyclase activity, LLC-PK1 crude membranes were solubilized with 0.2% Lubrol PX (Table II) . Extensive Lubrol PX dose-ranging studies were done that found that lower concentrations did not inhibit AVP-stimulated adenylate cyclase activity and higher concentrations of Lubrol abolished GTPand forskolin-stimulated adenylate cyclase activity. Solubilization of LLC-PK, membranes significantly reduces (P < 0.05) basal, GTP-, and forskolin-stimulated enzyme activity. In solubilized membranes, AVP no longer stimulates adenylate cyclase activity, while both GTP and forskolin significantly (P < 0.05) increase (4.5-and 5.8fold, respectively) enzyme activity over basal values. ATPyS (10-4 M) significantly inhibits forskolin-stimulated adenylate cyclase activity by 56% in intact and 48% in solubilized membranes. These results suggest that ATPyS does not require an intact plasma membrane environment that contains a functional AVP receptor to inhibit adenylate cyclase activity.
ATPyS is a chemically stable ATP analogue that may be resistant to ecto-nucleotidase-mediated degradation to adenosine. However, to insure that ATPyS inhibition of adenylate cyclase is not mediated by an A, adenosine receptor, the effect ofIBMX, an A, type adenosine receptor antagonist, was examined ( Fig. 6, panel B ). ATPyS inhibition of AVP-stimulated adenylate cyclase activity is the same in the presence and absence of IBMX suggesting an A, adenosine receptor-independent effect.
In some cell types, P2 receptor agonists stimulate phospholipase A2 activity (27) . Activation of phospholipase A2 could generate arachidonic acid metabolites which potentially inhibit adenylate cyclase activity. To determine ifATPyS inhibition of adenylate cyclase activity is mediated via phospholipase A2, the effects of l0-4 M quinacrine, a phospholipase A2 inhibitor, were studied ( Fig. 6 A) . ATPTS inhibition of AVP-stimulated adenylate cyclase activity is the same in the presence and absence ofquinacrine suggesting a phospholipase A2 independent effect.
Role of G proteins in ATPyS inhibition of agonist-stimulated adenylate cyclase activity in LLC-PK, membranes.
Previous studies suggest that P2y receptors may be coupled to inhibition of adenylate cyclase activity via a GTP binding protein (5, 7, 28) . We therefore examined the effect of ATPyS on AVP-and forskolin-stimulated adenylate cyclase activity in the presence and absence of pretreatment with 1.0 ,ug/ml pertussis forskolin-stimulated adenylate cyclase activity was the same in the presence and absence of pertussis toxin. Similar results were observed with 10.0 and 100.0 ,gg/ml of pertussis toxin.
Further studies were done to evaluate the possibility that the effect of ATPyS to inhibit adenylate cyclase activity is mediated by a pertussis toxin-insensitive G protein. In these studies, we used GDPJ3S, a stable analogue ofGDP which prevents G protein activation by preventing dissociation of the a subunit. Pretreatment of LLC-PK, membranes with GDP1#S consistently and significantly reduced (by -50%) the effect of ATPyS to inhibit AVP-and forskolin-stimulated adenylate cyclase activity (Table III) . Together, these results suggest that the inhibitory effect of ATPyS on AVP-and forskolin-stimulated adenylate cyclase activity may be mediated in part by a pertussis toxin-insensitive G protein.
Role ofprotein kinase C in A TPyS inhibition of agoniststimulated adenylate cyclase activity in LLC-PK, cells. In many cells, P2Y purinergic receptors stimulate phospholipase C-catalyzed phosphoinositide hydrolysis and/or calcium mobilization (5) (6) (7) 28) . To our knowledge, an effect of P2Y receptor agonists to activate protein kinase C has not been directly demonstrated. We first determined that a calciumand phospholipid-dependent protein kinase, which can be activated by the phorbol ester PMA and by the diacylglycerol diolein, is present in LLC-PKI cells (Table IV) . In these cells, PMA (l0-7 M), a known activator of protein kinase C (22, 23), increased total protein kinase C from a control value of 1.039±0.2 to 1.590±0.19 nmol 32p mg-' min' (P < 0.05), and translocated protein kinase C from a soluble to a particulate cell fraction (78±7 to 32±5% soluble, n = 7, P < 0.05). To determine if ATPyS activates protein kinase C in these cells, the studies depicted in Fig. 7 were carried out in intact LLC-PK1 cells. ATPTS exerted dose-dependent effects of protein kinase C activity with concentrations of 1010 through I0`s M significantly increasing activity over basal values. In these studies, basal protein kinase C activity averaged 1.056±0.13 nmol 32p mg-' min'. At 10-10 through 10-3 M, ATP-yS decreased the soluble and increased the particulate form of total protein kinase C activity by 10±2%. Previously, we have shown that activation and translocation of protein kinase C activity can induce a heterologous desensitization of adenylate cyclase activity in cultured renal epithelial cells (22, 23) . To Table. by 26±3% in the absence and 22±2% in the presence of 10-7 M H-7.
Effect ofA TPyS on LLC-PK1 cellular cAMP phosphodiesterase activity. There is evidence that ATP can regulate cAMP hydrolysis (29, 30) . We therefore examined the effect ofATP'yS on cAMP phosphodiesterase activity in particulate and soluble fractions from LLC-PK, cells (Table V) . ATPyS at 10-3 M reduced total and high affinity forms ofcAMP phosphodiesterase activity by 35 and 26% respectively in a particulate fraction.
In soluble fraction, ATPyS at IO-' and IO-' M decreased total cAMP phosphodiesterase activity by 32%.
Discussion
There is limited information on the presence and functional significance of ATP-responsive receptors on renal epithelial cells. In these studies, we find that the nonhydrolyzable ATP analogue, ATPyS, exerts a significant effect to inhibit AVPstimulated cAMP formation in intact LLC-PK, cells. Since these cells were pretreated with a cAMP phosphodiesterase inhibitor, the results suggest that ATPyS inhibits AVP-stimulated adenylate cyclase activity. We confirmed this by directly measuring adenylate cyclase activity in crude LLC-PK, membranes. In these studies, ATP and several analogues exert dosedependent effects to inhibit basal, GTP-, AVP-, and forskolin- membranes. An effect of P2y receptor agonists to inhibit cAMP accumulation in hepatocytes and FRTL thyroid cells has recently been reported (5, 7) . Our results supporting a P2y type of ATP receptor in mediating ATP effects are solely dependent upon the rank order potency of several ATP analogues studied in other tissues (1, 3, 5, 7) . Thus, further studies will be necessary to document the exact nature ofthe ATP receptor present in renal epithelial cells (31) . It is possible that some of the effect of ATP-yS and other ATP analogues to inhibit agonist-stimulated adenylate cyclase activity in LLC-PK1 membranes could be related to an action ofthe ATP analogues to act as a pseudosubstrate for adenylate cyclase. Indeed in plasma membranes, we observed a biphasic effect of ATPyS to inhibit AVP-stimulated adenylate cyclase activity with modest (25-40%) inhibition occurring at 10-8 through l0-' M and a striking further inhibition occurring at l0-' M. Although some of ATPyS inhibition of AVP-stimulated adenylate cyclase activity may be due to pseudosubstrate effect, particularly at high concentrations of ATPyS, there are several factors that suggest the presence of functional external ATP receptors on LLC-PK1 cells. Thus, at l0-4 M, ATPyS significantly inhibits AVP-stimulated cAMP accumulation in intact LLC-PK, cells. Also, GDP#S significantly prevents ATP~yS inhibition ofagonist-stimulated adenylate cyclase activity in LLC-PK, membranes, an effect not readily explained if ATP~yS were acting solely as a pseudosubstrate. Finally, exposure of intact LLC-PK, cells to concentrations of ATPyS from 10-10 through 10-6 M significantly increases protein kinase C activity in these cells. Together, these observations support the presence of functional ATP-responsive receptors on LLC-PK, cells.
We undertook several studies to clarify the mechanism whereby ATP-responsive receptors inhibit agonist-stimulated adenylate cyclase activity. Solubilization of LLC-PK, membranes resulted in loss of adenylate cyclase response to AVP. However, in these solubilized membranes, both GTP and forskolin significantly stimulated adenylate cyclase activity and ATPyS inhibited forskolin-stimulated enzyme activity. These findings demonstrate that ATPyS can act independent of an AVP receptor to inhibit adenylate cyclase activity. Pretreatment ofLLC-PKI membranes with either IBMX or quinacrine did not prevent ATPyS inhibition ofadenylate cyclase activity, suggesting that neither Al adenosine receptors nor phospholipase A2 are involved in this process.
The effect of P2Y receptor agonists to inhibit adenylate cyclase activity in hepatocytes and in FRTL-5 thyroid cells has been reported to be pertussis toxin sensitive (5, 7) . We did not find that exposure to very high concentrations of pertussis toxin attenuated the effect of ATPyS to inhibit either AVPor forskolin-stimulated adenylate cyclase activity. Previously, in physiologic studies, we have found that pertussis toxin can reverse the effect of a2 adrenergic agonists to inhibit AVP action in mammalian collecting tubular epithelia (32) . The reasons for the discrepancy between our results in LLC-PKI cells and the results ofothers in hepatocytes and dedifferentiated thyroid cells are not clear. In other studies in LLC-PK, cells, Weinberg and collaborators did not find that pertussis toxin pretreatment attenuates the effect of exogenous ATP to increase free cyto-solic calcium activity ( 19) . Also, recent preliminary studies by Lederer et al., in AVP-responsive mammalian collecting tubular cells, found that pertussis toxin does not reverse the inhibitory effect of ATP on AVP-stimulated hydroosmotic response (21) . We performed additional studies to explore the possibility that a pertussis toxin-insensitive G protein mediates the effect of ATPyS to inhibit AVP-stimulated adenylate cyclase activity. In these studies, we used GDP,6S, a non-hydrolyzable GTP analogue that prevents G protein activation. In paired studies, GDP3S consistently attenuated the effect of ATPyS to inhibit AVP-and forskolin-stimulated adenylate cyclase activity. Our results suggest the possibility that ATPyS inhibition ofadenylate cyclase activity involves a pertussis toxin-insensitive G protein. However, to date, a pertussis toxin-insensitive G protein linked to inhibition of adenylate cyclase activity has not been demonstrated. Thus, further studies are clearly needed to substantiate and clarify the role ofG proteins in ATP inhibition of adenylate cyclase activity in LLC-PK, cells.
In virtually all cell types studied to date, including AVP-responsive LLC-PK, and mammalian collecting tubular cells, ATP and its analogues activate a phosphoinositide-specific phospholipase C with subsequent formation of IP3 and mobilization of intracellular calcium stores (5-7, 19, 21, 27, 28 ). An effect ofATP to activate protein kinase C has not been directly demonstrated. We found that LLC-PK, cells contain a calcium and diacylglycerol activated protein kinase. The specific activity of this enzyme was significantly greater and the basal cellular location of the enzyme different than we observed previously in primary cultures of collecting tubular cells (22, 23) . In these studies, exposure of intact LLC-PK, cells to the phorbol ester PMA and to ATPyS consistently and significantly increases total protein kinase C activity. Activation of protein kinase C has been reported to both potentiate and inhibit agonist-stimulated adenylate cyclase activity in AVP-responsive renal epithelial cells (22, 23, 33) . To determine ifactivation of protein kinase C is responsible for the observed ATP-yS inhibition of adenylate cyclase activity, cells were pretreated with high concentrations of two structurally dissimilar inhibitors ofprotein kinase C. Neither ofthese agents attenuate the effect of ATPyS to inhibit AVP-stimulated adenylate cyclase activity, suggesting a protein kinase C-independent effect.
In view of suggestions that the process of cAMP hydrolysis may be regulated by ATP, we measured cAMP phosphodiesterase activity in LLC-PK, cell fractions. ATPyS at high concentrations exerts a modest inhibitory effect on cAMP phosphodiesterase activity comparable to that seen previously in homogenized brain and rat kidney (29, 30) . These observations suggest the potential for ATP to act at more than one site to regulate cAMP metabolism.
The results of our studies suggest that ATP responsive receptors are linked to two signal transduction systems in LLC-PK1 cells. Other purinergic receptors, particularly the Al adenosine receptor, appear coupled to two signal transduction systems in renal epithelial cells (9, 13, 19, 34, 35) . In this regard, Al receptor agonists inhibit cyclic AMP formation, increase cytosolic calcium activity, and stimulate phosphoinositide turnover (9, 13, 19, 34, 35) . In other renal epithelial cells, other hormones such as parathyroid hormone and AVP may also be linked to both the protein kinase A and protein kinase C signal transduction pathways (36, 37) . Our results do not establish if ATP receptors are coupled to the two signal transduction pathways by two separate receptors or by a single receptor with coupling through different G proteins. Although further studies will be required to clarify this issue, the work of Okajima et al. in rat hepatocytes suggests that distinct ATP receptors are linked to each signal transduction system (5) .
In summary, our studies suggest the possibility that functional P2Y purinoceptors are present in LLC-PK1 cells and are coupled to inhibition of adenylate cyclase and stimulation of protein kinase C activity. ATP receptor inhibition ofadenylate cyclase activity appears independent ofAVP and Al adenosine receptors and phospholipase A2 and protein kinase C activity. The effects ofATP receptors to inhibit adenylate cyclase activity may be transduced by a pertussis toxin-insensitive G protein. The presence of functional ATP receptors in renal epithelial cells suggests the potential for these receptors to modulate cellular transport processes. Studies in various renal epithelia suggest that ATP receptors may regulate sodium, chloride, and potassium transport (17, 18, 20) . Finally, there are multiple potential sites of origin for extracellular ATP including release during neurotransmission and cellular exocytosis (1).
